as 12-11-2024 4:00pm EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
Founded: | 1999 | Country: | United States |
Employees: | N/A | City: | ROCKVILLE |
Market Cap: | 375.0M | IPO Year: | 2021 |
Target Price: | $9.50 | AVG Volume (30 days): | 753.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.34 | EPS Growth: | N/A |
52 Week Low/High: | $3.17 - $5.55 | Next Earning Date: | 11-06-2024 |
Revenue: | $45,599,000 | Revenue Growth: | 19.85% |
Revenue Growth (this year): | -7.17% | Revenue Growth (next year): | 21.24% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Erck Stanley C | MXCT | Director | Nov 1 '24 | Sell | $3.72 | 47,689 | $177,403.08 | 269,118 | |
Johnston John Joseph | MXCT | Director | Oct 28 '24 | Sell | $3.72 | 3,000 | $11,166.00 | 141,950 | |
Erck Stanley C | MXCT | Director | Oct 1 '24 | Sell | $3.75 | 47,689 | $178,751.93 | 269,118 | |
Johnston John Joseph | MXCT | Director | Sep 26 '24 | Sell | $3.82 | 3,000 | $11,460.00 | 141,950 |
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
MT Newswires
3 days ago
GlobeNewswire
3 days ago
Simply Wall St.
21 days ago
GlobeNewswire
a month ago
GuruFocus.com
a month ago
Zacks
a month ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.